Seeking Alpha

Amarin Pharmaceuticals (AMRN) +15.5% premarket as U.S. patent examiners appear poised to approve...

Amarin Pharmaceuticals (AMRN) +15.5% premarket as U.S. patent examiners appear poised to approve a family of key patents that could protect its AMR101 prescription fish oil pill from generic competition through 2030. Jefferies is bullish on the prospects for approval, reiterating its Buy rating on the shares and raising its target price to $26 from $24.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs